vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $38.3M, roughly 2.2× ImmunityBio, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -161.8%, a 184.6% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 407.0%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-71.3M).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
FDMT vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $38.3M |
| Net Profit | $19.4M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | 17.3% | -169.0% |
| Net Margin | 22.8% | -161.8% |
| Revenue YoY | 8508900.0% | 407.0% |
| Net Profit YoY | 139.1% | -4.7% |
| EPS (diluted) | $0.43 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $38.3M | ||
| Q3 25 | $90.0K | $32.1M | ||
| Q2 25 | $15.0K | $26.4M | ||
| Q1 25 | $14.0K | $16.5M | ||
| Q4 24 | $1.0K | $7.6M | ||
| Q3 24 | $3.0K | $6.1M | ||
| Q2 24 | $5.0K | — | ||
| Q1 24 | $28.0K | — |
| Q4 25 | $19.4M | $-61.9M | ||
| Q3 25 | $-56.9M | $-67.3M | ||
| Q2 25 | $-54.7M | $-92.6M | ||
| Q1 25 | $-48.0M | $-129.6M | ||
| Q4 24 | — | $-59.2M | ||
| Q3 24 | $-43.8M | $-85.7M | ||
| Q2 24 | $-35.0M | — | ||
| Q1 24 | $-32.4M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.3% | -169.0% | ||
| Q3 25 | -67983.3% | -173.5% | ||
| Q2 25 | -396373.3% | -269.8% | ||
| Q1 25 | -383007.1% | -390.1% | ||
| Q4 24 | — | -919.0% | ||
| Q3 24 | -1704400.0% | -1314.3% | ||
| Q2 24 | -849120.0% | — | ||
| Q1 24 | -136200.0% | — |
| Q4 25 | 22.8% | -161.8% | ||
| Q3 25 | -63195.6% | -209.8% | ||
| Q2 25 | -364386.7% | -350.3% | ||
| Q1 25 | -342657.1% | -784.9% | ||
| Q4 24 | — | -783.4% | ||
| Q3 24 | -1461433.3% | -1404.0% | ||
| Q2 24 | -699060.0% | — | ||
| Q1 24 | -115717.9% | — |
| Q4 25 | $0.43 | $-0.06 | ||
| Q3 25 | $-1.01 | $-0.07 | ||
| Q2 25 | $-0.98 | $-0.10 | ||
| Q1 25 | $-0.86 | $-0.15 | ||
| Q4 24 | — | $-0.08 | ||
| Q3 24 | $-0.79 | $-0.14 | ||
| Q2 24 | $-0.63 | — | ||
| Q1 24 | $-0.66 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $-500.5M |
| Total Assets | $566.7M | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $242.8M | ||
| Q3 25 | $305.1M | $257.8M | ||
| Q2 25 | $293.2M | $153.7M | ||
| Q1 25 | $321.4M | $61.6M | ||
| Q4 24 | $424.9M | $149.8M | ||
| Q3 24 | $501.9M | $130.4M | ||
| Q2 24 | $541.9M | — | ||
| Q1 24 | $525.9M | — |
| Q4 25 | $505.7M | $-500.5M | ||
| Q3 25 | $369.0M | $-524.3M | ||
| Q2 25 | $420.9M | $-570.7M | ||
| Q1 25 | $469.7M | $-591.4M | ||
| Q4 24 | $510.6M | $-489.1M | ||
| Q3 24 | $552.9M | $-745.1M | ||
| Q2 24 | $588.3M | — | ||
| Q1 24 | $600.6M | — |
| Q4 25 | $566.7M | $501.9M | ||
| Q3 25 | $424.0M | $519.0M | ||
| Q2 25 | $473.6M | $402.1M | ||
| Q1 25 | $515.7M | $303.8M | ||
| Q4 24 | $560.4M | $382.9M | ||
| Q3 24 | $604.0M | $364.6M | ||
| Q2 24 | $620.1M | — | ||
| Q1 24 | $629.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $-70.4M |
| Free Cash FlowOCF − Capex | $28.5M | $-71.3M |
| FCF MarginFCF / Revenue | 33.5% | -186.2% |
| Capex IntensityCapex / Revenue | 0.1% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $-70.4M | ||
| Q3 25 | $-46.5M | $-68.9M | ||
| Q2 25 | $-43.4M | $-79.7M | ||
| Q1 25 | $-47.8M | $-85.9M | ||
| Q4 24 | $-134.6M | $-85.1M | ||
| Q3 24 | $-29.4M | $-98.8M | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-29.1M | — |
| Q4 25 | $28.5M | $-71.3M | ||
| Q3 25 | $-46.6M | $-69.6M | ||
| Q2 25 | $-43.4M | $-80.8M | ||
| Q1 25 | $-48.4M | $-87.0M | ||
| Q4 24 | $-138.4M | $-87.3M | ||
| Q3 24 | $-31.2M | $-101.6M | ||
| Q2 24 | $-30.6M | — | ||
| Q1 24 | $-29.8M | — |
| Q4 25 | 33.5% | -186.2% | ||
| Q3 25 | -51765.6% | -217.2% | ||
| Q2 25 | -289620.0% | -305.9% | ||
| Q1 25 | -345635.7% | -526.9% | ||
| Q4 24 | -13837100.0% | -1155.4% | ||
| Q3 24 | -1038966.7% | -1663.2% | ||
| Q2 24 | -611840.0% | — | ||
| Q1 24 | -106421.4% | — |
| Q4 25 | 0.1% | 2.4% | ||
| Q3 25 | 101.1% | 2.3% | ||
| Q2 25 | 440.0% | 4.1% | ||
| Q1 25 | 4507.1% | 6.8% | ||
| Q4 24 | 378600.0% | 28.0% | ||
| Q3 24 | 59266.7% | 45.7% | ||
| Q2 24 | 6980.0% | — | ||
| Q1 24 | 2535.7% | — |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
